Find link

language:

Find link is a tool written by Edward Betts.

searching for Endothelin A receptor 8 found (10 total)

Sitaxentan (711 words) [view diff] exact match in snippet view article find links to article

Langleben D, McLaughlin VV, et al. (November 2007). "Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension

Endothelin 1 (287 words) [view diff] exact match in snippet view article find links to article

cytokine activity endothelin B receptor binding protein binding endothelin A receptor binding Cellular component cytoplasm Weibel-Palade body basal part

Zibotentan (273 words) [view diff] case mismatch in snippet view article find links to article

K, et al. (September 2011). "Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients

Atrasentan (515 words) [view diff] exact match in snippet view article find links to article

Neuger AM, et al. (March 2008). "Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line

Bosentan (1,113 words) [view diff] exact match in snippet view article find links to article

TH, Gottlieb SS, Hare JM, Slawsky MT, et al. (June 2000). "Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with

Darusentan (186 words) [view diff] exact match in snippet view article find links to article

Lüscher TF, Ruschitzka F (August 2010). "Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension" (PDF)

FARP2 (488 words) [view diff] exact match in snippet view article find links to article

guanine nucleotide exchange factor in the signaling pathway from the endothelin A receptor to JNK". The Journal of Biological Chemistry. 278 (32): 29890–900

BQ-123 (870 words) [view diff] no match in snippet view article find links to article

"Conformational study of cyclo[D-Trp-D-Asp-Pro-D-Val-Leu], an endothelin-A receptor-selective antagonist". FEBS Letters. 296 (1): 1–6. doi:10